Effect of Liraglutide in Obese Women With Polycystic Ovary Syndrome
- Status
- CompletedResults none
- Why it is watched
- non-weight indication: endocrine, other_emerging
- Who it enrolls
- age 18 Years to 45 Years; female; no BMI minimum stated; conditions: Polycystic Ovary
- Interventions
- liraglutide; Metformin
- Conditions
- Polycystic Ovary
- Phase and size
- Phase 3 · 183 participants
- Dates
- Start 2024-08-01
Primary completion 2025-11-30 - Sponsor
- Beni-Suef University (Other)
- Last checked
- Sep 13, 2026
01Endpoints
What the trial will measure
- Insulin Resistance (HOMA-IR)6-months
02Eligibility
Who can take part
Inclusion Criteria: * women aged 18-45 years * Poly cystic ovary syndrome based on the Rotterdam criteria Exclusion Criteria: 1. congenital adrenal hyperplasia, 2. poorly controlled thyroid disease 3. Taking antidiabetic drugs which can affect insulin resistance 4. chronic kidney disease 5. liver dysfunction (AST or ALT 6. Documented use of oral hormonal contraceptives and hormone-releasing implants 7. intolerance or allergy to liraglutide or metformin
03Change log
Registry changes
No changes recorded since the trial was added.